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Abstract
Primary immunodeficiencies (PID) comprise a diverse group of clinical disorders with varied
genetic defects. Paradoxically, a substantial proportion of PID patients develop autoimmune
phenomena in addition to having increased susceptibility to infections from their impaired
immunity. Although much of our understanding comes from data gathered through experimental
models, there are several well-characterized PID that have improved our knowledge of the
pathways that drive autoimmunity. The goals of this review will be to discuss these
immunodeficiencies and to review the literature with respect to the proposed mechanisms for
autoimmunity within each put forth to date.
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INTRODUCTION
Primary immunodeficiencies (PID) comprise a diverse group of more than 150 inherited and
sporadic disorders. For some, an underlying genetic mutation has been identified, and for
others, the defect is not yet known. While clinical characteristics vary, all PID lead to
increased susceptibility to infection. Additionally, these patients somewhat paradoxically
develop autoimmune phenomena more frequently than the general population [1].
Central tolerance drives the deletion of the majority autoreactive T and B cells. Even within
healthy individuals, a few of these cells likely escape the thymus, but peripheral mechanisms
normally prevent reactivity. In the same way that genetic defects may contribute to
immunodeficiency and the abnormal development and maintenance of T and B cells, these
defects may predispose PID patients to autoimmune phenomena. At this time, accepted
theories of autoimmunity within PID center on failure of mechanisms of tolerance but also
extend to include mechanisms of apoptosis or proliferative defects, signaling pathway or
immune-mediated clearance defects, or aberrations in innate cellular mechanisms.
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Frequently, more than one mechanism may be responsible for the autoimmune
manifestations present in a single PID.
Although much of our understanding comes from data gathered through experimental
models, there are several well-characterized PID that have improved our knowledge of the
pathways that drive autoimmunity. The goals of this review will be to discuss these
immunodeficiencies and review the literature with respect to the proposed mechanisms for




Central tolerance is the deletion of autoreactive T cells that recognize self-peptides
presented on thymic epithelium primarily under the direction of the autoimmune regulator
(AIRE) gene. Thus, autoimmune mechanisms that may involve defects in central tolerance
are best observed in the primary immunodeficiency autoimmune polyendocrinopathy,
candidiasis, and ectodermal dystrophy (APECED) which results from a mutation in AIRE.
AUTOIMMUNE POLYENDOCRINOPATHY, CANDIDIASIS AND ECTODERMAL
DYSPLASIA—Within the thymus, AIRE controls the expression of a wide array of self-
peptides found in peripheral organs, such as insulin, thyroid peroxidase, thyroglobulin, 21-
hydroxylase, and myelin basic protein, and it is responsible for the maintenance of thymic
epithelial progenitor cells [2–4]. The zinc-finger domain of AIRE functions to mediate the
transfer of ubiquitin to specific proteins, hence targeting them to a variety of pathways such
as degradation [5–7]. Some peripheral self-peptides, such as C-reactive protein and
glutamic-acid decarboxylase, are also expressed in the thymus but are not controlled by
AIRE; the process of their expression is not well understood [4]. Although its major role and
function are thought to be through regulation of central tolerance, AIRE is also found to a
lesser degree in the spleen, pancreas, adrenal cortex, and lymph nodes, also suggesting a role
in peripheral tolerance [8, 9].
Typical clinical presentation of APECED includes the triad of cutaneo-mucus candidiasis
occurring by age 5 (in 75 %) followed by autoimmune-mediated hypoparathyroidism
occurring by age 10 (in 89 %) and adrenocortical failure occurring by age 15 (in 60 %) [9–
12]. Other autoimmune manifestations include hepatitis, primary biliary cirrhosis (PBC),
thyroiditis, hypogonadism, autoimmune hemolytic anemia (AHA), pernicious anemia, type
1 diabetes mellitus (T1DM), vitiligo, alopecia, keratoconjunctivitis, and ectodermal
dysplasia [6, 7, 9, 10, 13].
Autoimmunity in APECED is felt to result from failure of deletion of autoreactive T cells as
they undergo thymic selection. Evidence for this may be highlighted by the recent work of
Su et al. who showed in a murine model that failure of thymic expression of myelin protein
zero (controlled by AIRE) leads to CD4+ T cell infiltration in peripheral nerves, with
subsequent IFN-γ production and demyelination [14]. In this model, CD4+ T cells were
sufficient to transfer disease and mediate this Th1 response against peripheral nerves [14].
Failure of central tolerance appears to be the primary driving force for these autoimmune
manifestations, although further work on peripheral tolerance mechanisms may change our
understanding of these manifestations in the future. Teh et al. have also explored the
possibility of a second hit in peripheral tolerance that could lead to more rapid manifestation
of autoimmunity in APECED models [15]. Their murine work shows that absence of AIRE
coupled with absence of CBL-B, an inhibitor of signaling pathways (P13K and NFkB)
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normally activated by TCR-CD28 interaction in mature T cells, results in the rapid
progression of pancreatic autoimmune disease [15]. This rapid disease is hypothesized to
result from a combination of self-reactive T cells escaping from the thymus and the failure
of these cells to undergo anergy due to lack of CBL-B [15]. Further, it has been suggested,
in chronic cutaneo-mucus candidiasis patients with AIRE deficiency, that there is defective
Th17 differentiation (due to STAT 1/3 mutations), receptor function, and cytokine
production (IL17-F loss-of-function) as well as the development of autoantibodies against
type 1 interferons and Th17 cytokines that are contributing to disease pathogenesis [16].
B. PERIPHERAL TOLERANCE
As implicated above, the absence of peripheral tolerance mechanisms that induce anergy in
T cells through strength of TCR signaling may also contribute to the activation of
autoreactive cells. While not well elicited, it is also believed that the innate immune system
also contributes to peripheral tolerance. Diseases whereby one or some of these mechanisms
are speculated to be at play include hyper IgM syndrome (HIgM), which results from a
mutation of class switch genes, X-linked agammaglobulinemia (XLA) which results from a
mutation in Bruton’s tyrosine kinase (Btk), common variable emmunodeficiency (CVID) of
varied genetic defects, and immunodysregulation, polyendocrinopathy, enteropathy, X-
linked (IPEX), which results from a defect in forkhead box protein P3 (FoxP3).
HYPER IGM SYNDROME—HIgM syndrome is a group of defects in class switch
recombination that results in normal/high levels of IgM, low levels of IgA and IgG, and an
inability to produce memory B cells [8, 10, 17]. There are seven identified molecular
subsets: X-linked defect in CD40 ligand (type 1, 70 %), autosomal recessive/dominant
defect in activation-induced cytidine deaminase (AID) (type 2, <1 %), autosomal recessive
defect in CD40 (type 3, 10 %), autosomal recessive defect in uracil-DNA-glycosylase
(UDG) (type 5, 5 %), X-linked defect in nuclear factor kappa B essential modulator
(NEMO) (type 6, 1–2 %), and defect in IkBα (type 7); type 4 is an unknown defect [17–19].
Autoimmune manifestations most frequently occur in patients with AID (25 %), NEMO (23
%), and CD40L (20 %) defects. These patients may develop AHA, IBD, and polyarteritis [8,
10, 20]. Additionally, those with AID and CD40L defects may develop thyroiditis and
cytopenias (ITP in AID and neutropenia in CD40L), while those with AID defects have
uniquely developed hepatitis, uveitis, and T1DM [8, 10, 20].
The proteins described above are critical components in signaling and DNA recombination
pathways that result in immunoglobulin class-switching and cellular activation. Normally,
binding of CD40 (found on B cells and antigen-presenting cells) to transiently expressed
CD40 ligand (CD40L) (found on activated T cells) induces a cytoplasmic domain to bind to
TNF-receptor-associated-factor (TRAF) proteins, which in turn leads to further downstream
transcription effects mediated by nuclear factor (NF)-kB. This signal results in B cell growth
and differentiation, germinal center formation, and immunoglobulin class switching as well
as elimination of autoreactive B cells in the bone marrow or periphery (as seen in mouse
models) [8, 17, 18, 21]. CD40-CD40L also provides a co-stimulatory signal for T cell
activation and primes T lymphocytes for antigen-presentation [17–19]. T cell activation is
also impacted by cytokine secretion from innate cells (such as antigen-presenting cells,
platelets, endothelial cells, and endothelial cells) expressing CD40; hence, impaired
functioning and maturation of these types of cells due to defects in CD40 may also impact T
cell regulation [17, 19, 22]. In addition, a loss of CD40L signaling affects thymic epithelial
cells, thus leading to a potential loss of development of T regulatory cells [17, 21, 23].
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X-LINKED AGAMMAGLOBULINEMIA—X-linked agammaglobulinemia (XLA) is the
result of a mutation in Bruton’s tyrosine kinase (Btk), a signal transduction molecule needed
in the process of B cell development, proliferation, and survival signaling [24]. These
patients have few to no circulating B cells due to arrest of the B cell development at the pro-
B stage [23, 25]. Clinical manifestations include bacterial sinopulmonary infection, eczema,
and diarrhea, with diagnosis usually occurring within the first few years of life [9].
Autoimmune manifestations include AHA, arthritis, alopecia, scleroderma,
dermatomyositis, inflammatory bowel disease (IBD), and T1DM [8, 9, 11, 25].
Mechanisms of autoimmunity may be similar to those of HIgM. Alternatively, abnormalities
in B cell receptor (BCR) signaling may also provide a possible explanation. Prior work by
Ng et al. suggests that absence of Btk contributes to a mechanism of inappropriate
continuous receptor editing by B cells (whereas receptor recombination is typically down-
regulated by signaling through the BCR) [24]. This enables B cells, including autoreactive B
cells, to overcome Btk-responsible maturation defects and escape to the periphery [24].
Because B cells rely on survival signaling through a Btk mechanism, it is theorized that
those cells with self-reactive receptors are able to survive in the periphery due to signaling
by self-antigens [24].
COMMON VARIABLE IMMUNE DEFICIENCY—Common variable immunodeficiency
is a heterogeneous disease of unclear inheritance and pathogenesis that causes loss of
memory B cells and isotype-switched B cells leading to hypogammaglobulinemia as well as
varied T cell phenotypes. Clinical manifestations largely include sinopulmonary infection,
lymphoid or granulomatous proliferative disorders, gastrointestinal disease, and
autoimmunity [10, 13]. CVID most commonly occurs sporadically in 80–90 % of patients in
their 2nd or 3rd decade of life [26]. There have been five genetic defects described, which
include the following: transmembrane activator and calcium-modulator and cyclophilin
ligand interactor (TACI), inducible costimulator (ICOS), B-cell activating factor (BAFF)
receptor, CD19 and mutS homolog 5 (MSH5) [8, 10], but the majority of patients have an
unknown molecular cause. TACI mutation is found in 10 % of patients with CVID and can
be inherited in an autosomal dominant manner [9]. This particular molecular group has a
higher incidence of autoimmunity associated with it, particularly autoimmune cytopenias,
albeit mutation of TACI receptor has also been found in normal controls [21].
Autoimmune manifestations are found in roughly 25 % of all CVID patients and may be the
earliest presentation of the disorder [27]. Autoimmune disorders include cytopenias (11 %),
idiopathic thrombocytopenia (ITP)/AHA (5–8 %), pernicious anemia (1–9 %), thyroiditis,
rheumatoid arthritis (RA) (1–10 %), IBD or villous atrophy disease (6–10 %), hepatitis,
PBC, alopecia, dermatomyositis, and vitiligo [10, 13, 20, 25, 26, 28–30]. Other
lymphoproliferative diseases are also seen, including interstitial pneumonia, sarcoid-like
granulomas (5–20 %), and lymphoma [11, 28, 29].
Although the mechanisms underlying CVID and autoimmune susceptibility are not well
defined, several theories have been proposed. These include B cell abnormalities in
peripheral tolerance, signaling and maturation, as well as loss of T regulatory cells (Tregs).
It is suggested that autoreactive B cell removal in CVID depends on appropriate BCR
signaling and may also be affected by impaired calcium signaling as seen in some B cell
populations in CVID [31–33]. Additionally, immune complexes and FcyRIIB signaling
provide negative feedback on B cells through inhibitory receptors; some hypothesize that
decreased levels of IgG may contribute to failure of this regulatory effect [33]. In support of
this, mouse models with a lupus-like disease have a loss of function of FcyRIIB and chronic
B cell activation with increased germinal center and plasma cell accumulation, suggesting a
loss of peripheral tolerance [32, 33]. Alternatively, altered B cell survival factors, as seen in
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CVID with B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL),
may contribute to autoreactive B cell survival [31, 33].
CVID patients may also have abnormalities in B cell sub-population maturation (such as
memory and class-switched memory B cells) [21, 31]. An increased population of immature
B cells has been associated with granulomatous and autoimmune disease, such as cytopenias
[27, 34]. This expanded CD21low subset has been shown to express a polyclonal and
unmutated BCR repertoire and has a higher percentage of auto-reactive clones that produce
autoantibodies against cytoplasmic structures [34]. The full elicitation of these mechanisms
is still under investigation.
T cell abnormalities in proliferation, differentiation, and signaling are also found in patients
with CVID and can directly affect humoral immune function through effects on B cell
maturation, survival, and function [28]. Additionally, Tregs are decreased in patients with
CVID, and this may be due to changes in the strength of TCR signaling that are important in
the development of tolerogenicity [20, 27, 33]. Cytokine aberrancies, such as IL-2 and 12
deficiencies, may also contribute to lack of elimination of autoreactive cells or other
suppressive pathways such as seen in dendritic cell influence on Tregs [27].
IMMUNODYSREGULATION, POLYENDOCRINOPATHY, ENTEROPATHY, X-
LINKED—IPEX results from a defect in the transcription factor FoxP3, which is crucial to
the development of T regulatory cells (Tregs) [3, 10, 12, 23, 35]. The disease typically
manifests as diabetes, thyroiditis, severe watery diarrhea, failure to thrive, and eczema
within the first few months of life [12, 36]. In most cases, IPEX is a fatal disease and causes
death before the age of two [10]. Other autoimmune manifestations that occur in 100 % of
patients include enteritis, urticaria, T1DM, AHA, cytopenias, membranous nephropathy,
pemphigoid nodularis, psoriasiform dermatitis, and alopecia [4, 8, 10, 12, 20, 23, 35, 36].
Less commonly, patients may develop vasculitis, sarcoidosis, hepatitis, vitiligo, and adrenal
failure [36].
Tregs form long-lasting synapses with antigen-presenting dendritic cells to inhibit effector T
cell responses and induce peripheral tolerance [4]. Mutation of FoxP3 leads to reduced
number and diversity of regulatory cells, thus allowing normally “hidden” antigenic epitopes
to remain exposed. The resulting stimulation and proliferation of CD4+ T cells leads to an
overproduction of inflammatory cytokines and the potential production of autoantibodies [4,
37]. Additionally, Tregs depend on IL-2 signaling for survival; hence, defects in IL-2
signaling (i.e. STAT5b, IL-2 receptor defects, IL-2 defects) can lead to an IPEX-like
syndrome despite having normal FoxP3 expression [16, 20, 38]. Interestingly, in mice with
FoxP3 deficiency, blocking two TNF receptors (OX40 and CD30) responsible for CD4+
memory and effector cell generation is protective against the development of autoimmune
disease [39].
DEFECTS IN CELLULAR GROWTH AND SURVIVAL
A. IMMUNOPROLIFERATION
In some PID, the development of T and B cells is abnormal, resulting in a pronounced
deficiency whereby the available lymphocyte repertoire clonally expands to fill the available
niche. Resultant autoreactive T and B cells escape and proliferate, and autoimmunity may
result. This concept is best observed in Omenn syndrome (OS) and DiGeorge syndrome,
which result from RAG1/2 and defective thymic development, respectively.
OMEN SYNDROME—Omenn syndrome (OS) is an autosomal recessive condition
primarily caused by mutations in RAG1 or RAG2, two enzymes necessary for T cell and B
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cell receptor arrangement [16, 40]. Failure of this process arrests T cell and B cell
development and results in decreased numbers of each [41]. Some patients with OS also
have decreased AIRE gene expression in the thymus and mononuclear cells, similar to that
seen in APECED [2, 4, 42]. Autoimmune manifestations occur in 100 % of cases and are
primarily directed against epithelium and the gastrointestinal tract; these include dermatitis,
alopecia, hepatitis, and diarrhea [9, 20]. Autoimmunity is felt to result from clonal expansion
that includes autoreactive T cells directed against a variety of autoantigens as well as
defective Treg production due to RAG defects [41].
DIGEORGE SYNDROME—DiGeorge syndrome is an autosomal dominant condition
resulting in partial or complete failure of T cell development due to lack of or defective
thymus development (as well as parathyroid and conotruncal regions of the heart),
secondary to chromosome 22q11 deletion in the majority of cases [16, 40]. While phenotype
varies significantly, many of these patients also have facial dysmorphisms, neuropsychiatric
disorders, cardiac abnormalities, parathyroid abnormalities, and deafness [43, 44].
Autoimmune manifestations are said to occur in 5–30 % of patients and are reported to have
included cytopenias, AHA, hepatitis, IBD, arthritis, psoriasis, vitiligo, and thyroiditis [8, 20,
25, 45–48].
It is presumed that rapid proliferation, such as in the case of OS or DiGeorge syndrome, may
also lead to the clonal expansion of autoreactive cells by favoring the selection of T cells
with a high affinity to self, as has been observed in T1DM, RA, Sjogren's syndrome, and
systemic lupus erythematosus (SLE) [49]. While lymphopenia may be the stimulus required
for proliferation, it has been suggested that several other “hits” may be required as a
predisposition to this phenomena; these theories include increased numbers of autoreactive
T cells due to failure of central or peripheral tolerance, restricted Treg diversity, impaired T
cell survival, and the presentation of self-antigens due to tissue or cellular damage [16, 37,
49]. Additionally, some argue that exogenous microbial exposure may play a role in this
mechanism, since lymphopenia in and of itself is not sufficient for homeostatic proliferation
or an increased propensity toward autoimmune disease [37].
B. APOPTOSIS
Cell death is important in the control of immune response. When cell death does not occur
as it should, inappropriate immune activation and persistence of aberrant cellular responses
may occur that could predispose to autoimmunity. This concept is best observed in the
primary immunodeficiency autoimmune lymphoproliferative syndrome (ALPS) which
results from mutation of proteins involved in programmed cell death signaling: Fas [CD95,
ALPS 0 (autosomal recessive) and ALPS 1a (autosomal dominant)], Fas ligand (ALPS 1b),
caspase 10 (ALPS IIa), or caspase 8 (ALPS IIb) [4, 10, 40, 50, 51]. There is one additional
ALPS subset (ALPS III) for which there is as yet no known molecular defect [40].
AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME)—ALPS results in a clinical
scenario of lymphocytosis and hypergammaglobulinemia, together with splenomegaly and
lymphadenopathy, due to mutations in programmed cell death proteins. Diagnosis is
typically made in early childhood [10, 12]. Autoimmune manifestations have been reported
in approximately 50–80 % of individuals and most often include cytopenias (ITP and
neutropenia) and AHA but also glomerulonephritis, optic neuritis, Guillain-Barre syndrome,
arthritis, cutaneous vasculitis, PBC, hepatitis, blistering dermatosis, and acquired factor VIII
deficiency [8, 10, 20, 51].
Fas is a member of the tumor necrosis factor (TNF) receptor family and is found on a
diversified array of both immune and non-immune cell lines as is its ligand, Fas ligand
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(FasL). It is upregulated upon lymphocyte activation and induces programmed cell death
several days later through the recruitment of death domains with subsequent signaling
through caspase and the Ras pathway [50, 51]. In ALPS, autoreactive lymphocytes
proliferate freely, and an increased burden of cellular debris may contribute to the
development of more and diverse autoreactive cells. In these patients, unchecked
autoreactive B cell stimulation leads to persistent autoantibody production, and autoreactive
T cells persist due to impaired T cell receptor mediated apoptosis [8, 49, 50]. Additionally,
when an increased burden of autoantigen and cellular debris overwhelms macrophage
clearance, exposed self-antigens become available to antigen-presenting cells, allowing for
the development of additional autoreactive T cells [1, 4, 52]. In a similar manner, toll-like
receptors (TLR) 3 and 9 of the innate immune system are also able to recognize and cross-
present DNA released from dying cells and may contribute to further expansion of
autoreactive T cells [4].
COMBINED IMMUNE DEFICIENCY SYNDROMES—ALPS is a prototypic example of
dysregulated apoptosis with predisposition to autoimmunity; however, one newly described
PID also points to defects in cell survival and function that are outside the Fas pathway.
Lopez-Herrera et al. identified hypogammaglobulinemia (of at least two classes—IgA, IgG,
IgM), autoimmunity [ITP, AHA, thyroiditis, myasthenia gravis (MG), atrophic gastritis],
and IBD or enteropathy in four patients with homozygous mutation in lipopolysaccharide
responsive beige-like anchor protein (LRBA) [53]. Interestingly, LRBA is found most
predominantly in immune cells and contains motifs important in compartmentalization of
signaling enzymes, signal transduction, vesicular trafficking, cytoskeleton assembly,
apoptosis, cell cycle, and transcription regulation [53]. B cells from this group of patients
fail to proliferate, differentiate into plasma cells, and class-switch [53]. These cells also
accumulate an abnormal number of organelles, suggesting a defect in autophagy, and EBV-
infected cells in these patients have increased susceptibility to apoptosis [53].
Interestingly, immune dysfunction in Chediak–Higashi syndrome (CHS) is hypothesized to
result from impaired vesicular trafficking due to mutations involving LRBA function. CHS
is an immunodeficiency syndrome that manifests as recurrent infection, progressive
neurological deterioration, hypopigmentation, and the accumulation of giant intracellular
vesicles [54]. LRBA shares similarity to CHS1/beige and A kinase anchor genes already
shown to be involved in CHS and to negatively impact the function of natural killer (NK)
cells, cytotoxic T cells and granulocytes [54]. Although the autoimmune diseases of LRBA
mutations are not overlapping with CHS, the neutropenia of CHS has been suggested to
potentially originate from autoimmune origins [55].
DEFECTS OF SIGNALING PATHWAYS
Cells of the immune system are dependent on numerous intracellular signaling pathways
leading to appropriate immune function. When signaling pathways are abnormal, impaired
cytokine production, immune activation, and cellular migration can lead to broad defects in
T, B, and innate immune cell function. This concept is best observed in Wiskott–Aldrich
syndrome (WAS), which results from an X-linked defect in Wiskott–Aldrich syndrome
protein (WASp) causing impaired actin polymerization and cytoskeletal function of
hematopoietic cells [1, 16].
WISKOTT–ALDRICH SYNDROME
WAS is clinically characterized by thrombocytopenia with bleeding, eczema, and recurrent
sinopulmonary infections and occurs in 1–10 per million males [1, 44, 52, 56]. Autoimmune
manifestations occur in 40–72 % of patients and have included cytopenias (typically
Todoric et al. Page 7













neutropenia), AHA, vasculitis, arthritis, angioedema, myositis, dermatomyositis, IBD,
hepatitis, uveitis, and renal disease [1, 10, 13, 20, 25, 40, 52, 56]. As many as 25 % of WAS
patients have multiple autoimmune diseases [1], and autoimmunity is associated with an
increased risk of malignancy and mortality [52]. Interestingly, the more mild X-linked form
of WAS has been most predominantly associated with autoimmune manifestations [1, 56].
T cells are affected by defective WASp. Because of impaired cytoskeleton function, patients
with WAS have unstable immune synapses and suboptimal signaling through the T cell
receptor (TCR) [4]. TCR-activation is dependent on the recruitment of nuclear factor of
activated T cell (NFAT 1 and 2), both of which are reduced in WAS patients and correlate
with diminished Th1 cytokine production [52]. T effector cells, normally eliminated after
prolonged exposure to antigen (including self-antigen), fail to undergo the same degree of
TCR-mediated apoptosis when lacking WASp [52], and Treg numbers and function are
deficient likely due to defective cytokine release and impaired intracellular granule
movement [1, 9, 16, 20, 23, 52, 56–59].
B cell receptor (BCR) interactions and signaling are also impaired; this is due to failure of
WASp interaction with tyrosine kinases, including Bruton’s tyrosine kinase (Btk) [52, 59,
60]. Consequently, there are fewer germinal centers and decreased migration, proliferation,
and survival of B cells [52, 56, 59]. WASp-deficient B cells also express fewer complement
receptors (CD21), contributing to an inability to effectively capture and present antigens and
a possible breakdown in peripheral tolerance [52].
Likewise, innate cell dysfunction also occurs in WAS patients [23, 56, 58]. For example,
natural killer (NK) cells demonstrate defective cytolytic function, and, in mouse models,
restoration of a normal natural killer T cell (NKT) population can prevent the onset of
diabetes, suggesting a role in autoimmunity [1]. Macrophage function is also impaired and
hypothesized to contribute to autoimmunity through an inability to clear apoptotic debris [1,
52]. Additionally, dendritic cells lacking WASp may contribute to autoimmunity due to a
proinflammatory cascade that results from an inability to negatively regulate type one
interferon production after stimulation of toll-like receptor 9 [61]. These types of
impairments are likely contributing factors in the development of autoimmunity in WAS.
DEFECTS OF IMMUNE MEDIATED CLEARANCE
An additional theory of autoimmune pathogenesis in PID is that of defects in antigen
clearance. In some instances, it has been proposed to be secondary to molecular mimicry
where increased susceptibility and recurrent infection ultimately results in tissue destruction,
cellular activation, and impaired debris clearance that may lead to targeting of self-proteins
and breaks in tolerance. This concept is one of the potential mechanisms theorized to be
relevant in selective IgA deficiency and deficiencies of the classical complement pathway.
SELECTIVE IgA DEFICIENCY
Selective IgA deficiency (IgAD) is the most common form of PID, occurring in
approximately 1 in 500 Caucasians [25, 44, 62], and is diagnosed when serum IgA levels are
≤7 mg/dL in a patient greater than 4 years old with normal levels of IgG and IgM [62, 63].
IgAD is associated with both organ-specific and systemic autoimmune manifestations in 7–
36 % of patients [62]. These have included SLE (1–5 %), RA (2–4 %), and celiac disease
(10–20 %) as well as sporadic cases of urticaria, thyroiditis, AHA, ITP, T1DM, MG,
psoriasis, vitiligo, and pemphigus [8, 11, 13, 20, 25, 62, 63]. The most common
hematological autoimmune manifestation is ITP occurring in 1 in 200 patients [62].
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The genetic defect responsible for selective IgA deficiency has not been elicited. However,
as circulatory B cells in IgAD express surface IgA but lack secretory IgA, it has been
suggested that a transcription or class switch defect may contribute to the clinical phenotype
[8]. Additionally, a mutation in transmembrane activator and calcium-modulator and
cyclophilin ligand interactor (TACI), a member of the tumor necrosis receptor family which
mediates isotype switching, was identified in one patient with selective IgAD [62]; TACI
mutation is also associated with CVID (see above). Genetic susceptibility linking IgA
deficiency and CVID with autoimmunity is suggested by a shared susceptibility locus on
chromosome 6 (DQ-DR) along with SLE, T1DM, thyroiditis, MG, and celiac disease [8,
63]. A genome-wide association study has revealed two additional non-HLA gene signals,
IFIHI (MDA-5) (also significantly associated with T1DM and SLE) and CLEC16A (also
significantly associated with T1DM and multiple sclerosis) [64].
At this time, autoimmune disease in IgAD is hypothesized to result from the lack of
clearance of antigens from mucosal surfaces with resultant immune complex deposition.
This leads to tissue damage and ongoing inflammation with subsequent exposure of
autoantigens and breakdown in peripheral tolerance [1, 13]. It has been proposed that these
reactive lymphocytes may proliferate when responding to autoantigens presented by
dendritic cells [1]. A second theory is that the lack of clearance of intraluminal antigens
(from diet or pathogens) with molecular mimicry to normal tissue or the exposure to
superantigens leads to a breakdown of peripheral tolerance [8, 63]. A third hypothesis, not
involving clearance defects but in line with CVID, is the lack of inhibitory signaling through
constitutively-expressed FcαR1 in patients with IgA deficiency [62].
COMPLEMENT DEFICIENCIES
Classical complement deficiencies are inherited in an autosomal recessive fashion and lead
to an increased risk of the development of systemic lupus erythematosus (SLE) depending
on the component affected [40]. SLE is found in 90 % of patients with C1q deficiency, 75 %
of patients with C4 complete deficiency, 50–65 % of patients with C1r/s deficiencies, and
10–30 % of patients with homozygous C2 deficiency [10, 20, 25]. Of these complement
component deficiencies, homozygous C2 deficiency is the most common, occurring in 1 in
10,000 to 1 in 30,000 Caucasians, and is caused by a premature stop codon [10]. Neither
heterozygous C2 deficiency nor homozygous C4B deficiency has been associated with
increased autoimmunity [10].
Each of these components is important in the clearance of immune complexes and other
apoptotic bodies. If this debris is not cleared, there is a hypothesized increased exposure of
intranuclear antigens leading to the formation of antinuclear antibodies (ANA) [8].
Alternatively, some argue that ANA are the result of tissue damage that occurs from
immune complex deposition (due to lack of clearance) as has been shown in burn patients in
which ANA are produced [8].
DEFECTS OF INNATE CELLULAR MECHANISMS
Innate immune cells contribute to the normal functioning of the adaptive immune system,
and defects may contribute to disease pathogenesis in autoimmunity. In these cases,
autoimmunity is hypothesized to result from inappropriate cellular activation and
inflammation and the failure of development of peripheral tolerance mechanisms. This
concept is best observed in chronic granulomatous disease (CGD) resulting from defective
granulocyte bactericidal activity.
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CGD occurs in 1 in 250,000 persons and is the result of one of four defects in the
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex [65, 66]. This
results in an inability to transfer an electron from NADPH to oxygen and produce reactive
oxygen species (ROS) superoxide [66, 67]. This functional phagocytic disorder presents
with recurrent abscesses, osteomyelitis, pneumonia, lymphadenitis, and granulomatous
formation [25]. There is one X-linked defect involving the component gp91phox (65 % of
cases) and three autosomal recessive defects involving the components p47phox (25 %),
p67phox (5 %), and p22phox (5 %) [66]. Those patients with X-linked disorders tend to
have more severe presentations, more severe infections, and earlier death [66].
Autoimmune manifestations most commonly include CGD-associated colitis (histologically
similar to Crohn’s disease) and discoid lupus [25, 68]. Other manifestations include
sarcoidosis, ITP, RA, juvenile arthritis, and celiac disease [25, 66, 68, 69]. Unaffected
carriers of the disease have also been reported to have an increased incidence of discoid
lupus [11, 65]. Preliminary molecular work suggests polymorphisms of myeloperoxidase
(MPO), FcγRIIa, and FcγRIIIb are associated with GI inflammation and granuloma
formation, while variant alleles of mannose binding lectin (MBL) and FCγRIIa are
associated more with rheumatological manifestations [69].
Autoimmune manifestations are hypothesized to result from impaired Treg production,
persistent cellular activation with loss of peripheral tolerance, and poor debris clearance
causing increased exposure to autoantigens. In vitro evidence has shown that ROS
production by macrophages leads to the development of Tregs [5]. Therefore, a ROS-
deficient state may lead to diminished Treg production and loss of peripheral tolerance [5,
67, 68]. Persistent cellular activation and inflammation may additionally occur due to
impaired ROS-driven apoptosis, silencing of inflammatory mediators (such as leukotrienes),
granulocyte apoptosis, or degradation of material [5, 67, 68]. Similarly, altered innate
pathogen recognition and chemotactic receptor expression may also affect cellular activation
and function [67]. Additionally, a defect in the kynuenine pathway (which favors immune
tolerance) may play a role as kynuenine replacement has been shown to reverse
inflammation in a mouse model of CGD [67]. Finally, poor debris removal (due to
decreased expression of phosphatidyl serine) may cause increased exposure to autoantigens
[65, 69]. These postulated mechanisms are still being studied in this PID.
CONCLUSIONS
The understanding of autoimmunity in PID has made great strides over the past years, due in
large part to gains in knowledge about PID mechanisms. As such, the above-described PIDs
highlight currently accepted theories of autoimmunity in these conditions (defects of
tolerance, apoptosis, immunoproliferation, signaling pathways, immune-mediated clearance,
and innate cellular mechanisms). Ongoing and future exploration are sure to push this
frontier forward, improving our insight into the pathogenesis of autoimmunity, revealing
new arenas for study, and, ultimately, providing targets for treatment for patients who suffer
the consequences of an immune system gone awry.
Abbreviations
APECED Autoimmune polyendocrinopathy candidiasis ectodermal dysplasia
HIgM Hyper IgM syndrome
XLA X-linked agammaglobulinemia
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CVID Common variable immunodeficiency
IPEX Immunodysregulation polyendocrinopathy enteropathy x-linked
OS Omenn syndrome
ALPS DiGeorge syndrome; Autoimmune lymphoproliferative syndrome
WAS Wiskott Aldrich syndrome
IgAD IgA deficiency
CGD Complement deficiency; Chronic granulomatous disease
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Table 1
Proposed mechanisms of autoimmunity in primary immunodeficiencies (PID).*
PID Genetic defect(s) Proposed major mechanisms of autoimmunity
Defects in tolerance
APECED AIRE Failure of deletion of autoreactive T cells; failure of anergy due to
loss of inhibitory signals
HIgM CD40, CD40L, AID, UDG, NEMO,
IkBα
Failure of deletion of autoreactive B cells; loss of Treg development;
deranged T cell activation by innate system
XLA Btk Similar to HIgM (see above); continuous BCR editing with
peripheral survival advantage for autoreactive B cells
CVID TACI, ICOS, BAFF-R, CD19, MSH5,
others unknown
Proliferation of autoreactive B cells due to impaired BCR-TCR
interactions, loss of FcyRIIB inhibitory signaling, or altered BAFF/
APRIL survival signaling; decreased Treg population due to cytokine
aberrancies or impaired TCR signaling
IPEX FoxP3 Decreased number and diversity of Treg cells; aberrant stimulation of
CD4+ T cells with subsequent production of autoantibodies
Defects in cellular growth and survival
OS RAG1/RAG2, +/−AIRE Autoreactive lymphocyte escape and proliferation; defective Treg
production
DiGeorge Syndrome Chromosome 22q11 deletion Failure of T cell development with autoreactive T cell escape;
restricted Treg diversity; tissue or cellular damage with autoantigen
exposure and formation of autoantibodies and autoreactive T cells
ALPS Fas, FasL, caspase 8 & 10 Persistence of autoreactive B and T cells due to failure of apoptosis;
impaired debris clearance with autoantigen exposure and formation
of autoantibodies and autoreactive T cells
Defects of signaling pathways
WAS WASp Impairment of cytoskeletal movement/migration, signaling pathways
and cytokine production needed for inhibition of the inflammatory
cascade, Treg stimulation, apoptosis, and TCR/BCR interactions;
impaired debris clearance (see above)
Defects of immune-mediated clearance
IgAD Unknown, possible TACI Impaired debris clearance (see above ALPS); bystander activation;
impaired inhibitory signaling
Complement Deficiencies C1q, C1r/s, C4, C2 Impaired debris clearance and tissue damage (see above ALPS)
Defects of innate cellular mechanisms
CGD NADPH oxidase complex components Defective production of reactive oxygen species contributing to
impaired Treg production and T cell apoptosis; impaired debris
clearance (see above, ALPS)
APECED polyendocrinopathy, candidiasis, and ectodermal dystrophy; AID activation-induced cytidine deaminase, AIRE autoimmune regulator;
ALPS autoimmune lymphoproliferative syndrome; APRIL a proliferation inducing ligand; BAFF-R B cell activating factor receptor; Btk Bruton’s
tyrosine kinase; CD40L CD40 ligand; CGD chronic granulomatous disease; CVID common variable immunodeficiency; FasL Fas ligand; FoxP3
forkhead box protein P3; HigM hyper IgM syndrome; ICOS inducible costimulator; IgAD selective IgA deficiency; IPEX immunodysregulation,
polyendocrinopathy, enteropathy, X-linked; MSH5 mutS homolog 5; NADPH nicotinamide adenosine dinucleotide phosphate; NEMO kappa B
essential modulator; OS Omenn Syndrome; TACI transmembrane activator and calcium-modulator and cyclophilin ligand interactor; UDG uracil-
DNA-glycosylase; WAS(p) Wiskott-Aldrich Syndrome (protein); XLA X-linked agammaglobulinemia
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